Two classes of ER inhibitors are currently approved for breast cancer treatment, selective estrogen receptor modulators (SERMs), exemplified by tamoxifen and raloxifene, and selective estrogen receptor downregulators (SERDs), such as fulvestrant and ICI-164384. This evidence concerns the gene ESR1 and breast cancer.